Nursing Pharmacology
Chapter 33-34: Cancer Chemotherapy Drug Practice Questions
Click on the correct answer.
This chemotherapeutic agent does not alkylate DNA but exhibits similarities with alkylating agent both in terms of resistance and mechanism of action.
- Platinum
- Ethyleneimines
- Nitrosoureas
- Nitrogen mustards
- Triazenes
Which one(s) of the following statements concerning busulfan is/are correct?
- Busulfan is classified as an alkyl sulfonate
- The principal therapeutic use of busulfan is in bone marrow transplantation, particularly in CML (chronic myelogenous leukemia).
- An example of an important toxicity associated with busulfan is pulmonary fibrosis.
- A & B
- B & C
- A, B & C
This/these drugs are examples of ethyleneimines/methylmelamines:
- Altretamine
- Thiotepa
- Both
- Neither
Mechlorethamine is described as belonging to this class of chemotherapeutic agent:
- Nitrosoureas
- Nitrogen mustards
- Triazenes
- None of the above
Choose the correct answer(s) concerning dacarbazine:
- Principal therapeutic use includes malignant melanoma
- Therapeutic use includes Hodgkin lymphoma
- Prominent side effect is nausea
- A & B
- B & C
- A & C
- A, B & C
In comparing the clinical uses of Dacarbazine and Temozolomide, which agent is more likely to be used for managing glioblastoma and astrocytoma?
- Temozolomide
- Dacarbazine
- One is no more likely to abuse than the other.
Choose the correct statement(s) concerning carmustine:
- This drug is classified as a nitrosourea compound.
- Carmustine exhibits activity towards glioblastoma multiforme
- Both
- Neither
Carmustine bone marrow as well as pulmonary toxicities depend upon lifetime cumulative dosing.
- True
- False
Among the nitrosourea-class of chemotherapeutic drugs, which one of the following is more likely to be used in treating islets of Langerhans cancers?
- Streptozotocin
- Carmustine
- Neither
Prominent nephrotoxicity which may progress to permanent tubular damage.
- Streptozotocin
- Dacarbazine
- Cyclophosphamide
- None of the above
If
you wish to return to the Table of Contents in ENGLISH, press
the RETURN button above. |
Otherwise, if the text is NOT displayed in English and
you are ready to leave this page,
Press here
to return to the Table of Contents
|